Phase 2 Completed N=16 Treatment

Pharmacokinetics of Advantage Arrest

Dental Caries

Source: ClinicalTrials.gov NCT04184271 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2020

Primary outcomePrimary: Observed Fluoride Urinary Recovery — 1.29 mg

Summary

The study aim is to characterize the kinetics of silver and fluoride after topical application of silver diamine fluoride.

Outcome Measures

Outcome	Result	p-value
PRIMARY Observed Fluoride Urinary Recovery	1.29	—
PRIMARY Observed Silver Tmax	5.3	—
PRIMARY Observed Silver Cmax	0.70	—
PRIMARY Observed Silver Baseline-Corrected Cmax	0.67	—
PRIMARY Observed Silver t1/2	46	—
PRIMARY Observed Silver 24 Hour Urinary Concentration	0.05	—

Eligibility Criteria

Inclusion Criteria

18 years or older, minimum 20 teeth, healthy, not taking prescription or OTC medications

Exclusion Criteria

pregnant, weighed less than 50 kg, had oral mucositis or ulcerative lesions, known sensitivity to silver or fluoride

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04184271). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.